<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-N8PHC8BA/715bb988-a328-4a7e-a54f-778bd1425a50/HTML"><dcterms:extent>22 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-N8PHC8BA/4b9a9c60-ae38-4aca-a6d4-97a57eabda91/PDF"><dcterms:extent>90 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-N8PHC8BA/8afe810c-6c93-4c6f-9afb-cd9deb90199a/TEXT"><dcterms:extent>18 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-N8PHC8BA"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2005</dcterms:issued><dc:creator>Debeljak, Andrej</dc:creator><dc:creator>Debevec, Lučka</dc:creator><dc:creator>Eržen, Janez</dc:creator><dc:creator>Kern, Izidor</dc:creator><dc:creator>Kovač, Viljem</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:39</dc:format><dc:format xml:lang="sl">7 strani</dc:format><dc:format xml:lang="sl">str. 115-121</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:19765465</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-N8PHC8BA</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="sl">bolniki</dc:subject><dc:subject xml:lang="en">Diagnosis</dc:subject><dc:subject xml:lang="en">diagnostika</dc:subject><dc:subject xml:lang="en">Lung Neoplasms</dc:subject><dc:subject xml:lang="en">Neoplasm Staging</dc:subject><dc:subject xml:lang="sl">Novotvorba, stadij</dc:subject><dc:subject xml:lang="sl">Pljučne novotvorbe</dc:subject><dc:subject xml:lang="sl">pljučni rak</dc:subject><dc:subject xml:lang="sl">preživetje</dc:subject><dc:subject xml:lang="sl">Preživetje, analiza</dc:subject><dc:subject xml:lang="sl">rak (medicina)</dc:subject><dc:subject xml:lang="en">Retrospective Studies</dc:subject><dc:subject xml:lang="sl">Retrospektivne študije</dc:subject><dc:subject xml:lang="en">Survival Analysis</dc:subject><dc:subject xml:lang="en">Therapy</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Characterization of lung cancer patients, their actual treatment and survival| experience of Slovenia|</dc:title><dc:description xml:lang="sl">Background. The aim of the study was to establish characteristics of lung cancer patients diagnosed at the University Clinic of Respiratory and AllergicDiseases Golnik in 1996, their selected and realized therapy, and survival. Methods. The retrospective study comprises 345 patients aged from 37to 90 years (mean 65), 285 males and 60 females. Performance status (Karnofsky): &gt; 80 in 171 patients, 60-80 in 130 and &lt; 60 in 44 patients. Mirroscopically confirmed tumour in 97%: by bronchoscopy 281, transthoracic needle biopsy 23, peripheral lymph nodes biopsy 12, sputum cytology 7, pleural(effusion) cytology 4, distant metastases biopsy 2, mediastinoscopy 1, autopsy 4 patients. Histology and/or cytology: squamous 131, adenocarcinoma 86, large cell 63, small cell 51, non-small cell 1, unclassified 2. Clinical staging of non-small cell lung cancer (NSCLC): stage I 63, stage ll 32, stage IIIA 48, stage IIIB 59, stage IV 77, undeterminable 2 patients. Staging in small cell lung cancer (SCLC): limited disease 24, extended disease 27 patients. Results. The selected primary oncological therapy was changed in 11%. Realized primary therapy: radiotherapy 102 (30%), surgery 77 (23%), chemotherapy 47 (14%), supportive treatment 111 (33%). In resected patients staging was correct in 46%, underestimated in 44%, overestimated in 10%. The overall five-year survival was 7.8% (median 6.2 months) and the five year survival of resected patients was 41.9% (median 33 months). The median survival of irradiated patients was 5.7 months, of supportively treated patients 2.5 months. The survival was significantly different according to theperformance status and stage. (Abstract truncated at 2000 characters)</dc:description><dc:description xml:lang="sl">Izhodišča. Namen raziskave je bil ugotoviti značilnosti bolnikov s pljučnim rakom, ki so bili diagnosticirani na Kliničnem oddelku za pljučne bolezni in alergijo Golnik v letu 1996. Prav tako smo želeli ugotoviti, kolikšna je bila razlika med izbranim in dejanskim zdravljenjem ter kakšno je bilo preživetje bolnikov. Metode. Retrospektivno smo analizirali dokumentacijo 345 bolnikov, starih od 37 do 90 let (mediana 65), 285 moških in 60 žensk. Telesna zmogljivost (Karnofsky): VVV 80 pri 171 bolnikih, 60-80 pri 130 in ZZZ60 pri 44 bolnikih. Tumor smo mikroskopsko potrdili pri 97% bolnikov, z bronhoskopijopri 281, s transtorakalno igelno biopsijo pri 23, z biopsijo perifernih bezgavk pri 12, s citološko preiskavo sputuma pri 7, s citološko preiskavo plevralnega izliva pri 4, z biopsijo oddaljenih zasevkov pri 2, z mediastinoskopijo pri 1 in z obdukcijo pri 4 bolnikih. Histološko in/ali citološko smo dokazali: pri 131 bolnikih epidermoidni, 86 žlezni, pri 63 velikocelični, pri 51 drobnocelični, pri 1 nedrobnocelični in pri 2 bolnikih neopredeljeni karcinom. Klinični stadij pri nedrobnoceličnem raku je bil v 63 primerih stadij I, v 32 stadij II, v 48 stadij IIIA, v 59 stadij IIIB, v 77 stadij IV, v 2 primerih pa stadija ni bilo mogoče določiti. Pri bolnikih z drobnoceličnim rakom smo ugotovili v 24 primerih omejeno obliko bolezni, v 27 pa razširjeno bolezen. Rezultati. Dejansko onkološko zdravljenje je bilo drugačno kot izbrano zdravljenje pri 11% bolnikov. Primarno smo z obsevanjem zdravili 102 (30%) bolnika, z operacijo 77 (23%), s kemoterapijo 47 (14%) ter s podpornim zdravljenjem 111 (33%) bolnikov. Pri operiranih bolnikih je bilklinični stadij pravilno določen pri 46% bolnikov, prenizko ocenjen pri 44%ter previsoko ocenjen pri 10% bolnikov. (Izvleček prekinjen pri 2000 znakih)</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-N8PHC8BA"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-N8PHC8BA" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-N8PHC8BA/4b9a9c60-ae38-4aca-a6d4-97a57eabda91/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-N8PHC8BA/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-N8PHC8BA" /></ore:Aggregation></rdf:RDF>